Montgomery

Researchers are evaluating treatment preference and satisfaction among adults in the United States diagnosed with schizophrenia who are prescribed xanomeline and trospium chloride (X/T) therapy. The study aims to understand how patients feel about their medication and how satisfied they are with their treatment experience. Participants will receive xanomeline and trospium chloride (X/T) therapy according to the product label. This treatment is being observed in a real-world setting without modifications, focusing on how patients use and respond to this medication combination. During the study, participants will report their medication preference through the Preference of Medication (POM) questionnaire at Month 1, Month 3, and Month 6. Treatment satisfaction will also be measured using the Medication Satisfaction Questionnaire (MSQ) at baseline and at Months 1, 3, and 6. Participants will provide their responses either electronically or on paper, in English or Spanish, over a period of at least six months.